Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shares in Big Technologies slide as legal row with ex-CEO ramps up

(Sharecast News) - Shares in Big Technologies came under pressure on Friday, after the AIM-listed firm's legal dispute with its founder deepened. Sara Murray was chief executive of Big Technologies, a provider of electronic monitoring services, until March this year, when she was sacked and referred to the Takeover Panel.

Big Technologies has since launched legal action against Murray, claiming she had extracted "significant sums" from the group - thought to be in excess of £19m - via undisclosed interests in various offshore shell companies.

In particular, the claims relate to Murray's relationship with Zinc Ltd, Monitoring Partners, RCP and Romelle, which held a stake of around 17% in Big Technologies at the time of its 2021 initial public offering.

Murray has denied the accusations. In June, she wrote to selected shareholders, claiming the board was "unfit for purpose" and that she did not "own or control any of the companies cited".

However, on Friday Big Technologies said it was seeking to expand its claim against Murray, which is now in the High Court.

It said: "Additional matters have now come to light which further materially adversely impact the position of the company and Buddi in the Buddi litigation. These matters centre on the forgery or deliberate falsification by Sara Murray of various documents, including board minutes of Buddi and emails."

The separate Buddi litigation alleges that when Big Technologies acquired Buddi in 2018, the claimants were wrongly forced or "induced through misrepresentation" to sell their shares. Nor were they given the opportunity to reinvest in Big Technologies.

Murray, who founded Buddi in 2005, denied the latest allegations when put to her, the company said.

Big Technologies said it had concluded that it and Buddi are "unlikely" to be able to successfully defend "material elements" of the claim.

However, it continued: "The claimants' case is still, in the company's view, flawed and is therefore denied on a number of other bases."

Alexander Brennan, chair, said: "The new developments announced today are of a very serious nature and have important implications for the company's proceedings against Sara Murray, as well as its position in the Buddi litigation.

"While the board has been successful in enabling the executive team to focus on the group's strategy and delivering for shareholders without the distraction of litigation, we very much hope mediation can be achieved so that all parties can move forward efficiently."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.